GLP-1’s function as an incretin, acting to stimulate insulin secretion and inhibit glucagon secretion, has been exploited pharmacologically for the purposes of limiting post-prandial hyperglycemia in T2DM [22], and GLP-1 receptor agonists have been demonstrated to promote weight loss [23]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.